Subepidermal lymphoid infiltrate | ||||
---|---|---|---|---|
Grade 1 (n=11) | Grade 2 (n=15) | Grade 3 (n=16) | Grade 4 (n=4) | |
The follow up time was calculated from the date of diagnosis. | ||||
Treatment: PUVA, psoralen + ultra violet A rays; IFNα, interferonα2b; CHOP, cyclophosphamide, doxorubicin, vincristin, and prednisone; RT, radiotherapy. Response to treatment: CR, complete remission; PR, partial remission; SD, stable disease. Status at last follow up: AW, alive and well; AD, alive with disease; DOD, died of disease; DNOD, died but not of disease. | ||||
M/F | 7/4 | 4/11 | 8/8 | 3/1 |
Mean age (range) | 60.18 (45–73) | 63.13 (45–76) | 56.5 (37–72) | 45.25 (28–61) |
Clinical patch | 11 | 13 | 12 | 0 |
Clinical plaque/nodule | 0 | 2 | 4 | 4 |
Stage | ||||
<IIA | 10 | 13 | 14 | 1 |
≥IIA | 1 | 2 | 2 | 3 |
Epidermotropism | ||||
Grade 1 | 4 | 2 | 3 | 3 |
Grade 2 | 4 | 8 | 8 | 1 |
Grade 3 | 3 | 5 | 5 | 0 |
Loss of T cell antigens | 11/11 | 12/13 | 16/16 | 4/4 |
T cell monoclonality | 8/11 | 14/15 | 13/16 | 4/4 |
Epididermal CD1a+ cells | ||||
Score 1 | 3 | 1 | 5 | 2 |
Score 2 | 5 | 9 | 6 | 1 |
Score 3 | 3 | 5 | 5 | 1 |
Treatment | ||||
PUVA | 1 | 2 | 0 | 0 |
PUVA+IFNα | 4 | 9 | 8 | 1 |
CHOP | 0 | 0 | 1 | 1 |
RT | 0 | 0 | 0 | 1 |
None | 6 | 4 | 7 | 1 |
Response to treatment | ||||
CR | 5 | 10 | 6 | 1 |
PR | 0 | 1 | 3 | 1 |
SD | 0 | 0 | 0 | 1 |
Relapse | 2 | 2 | 3 | 0 |
Status at last follow up | ||||
AW | 5 | 10 | 4 | 0 |
AD | 6 | 5 | 12 | 2 |
DOD | 0 | 0 | 0 | 1 |
DNOD | 0 | 0 | 0 | 1 |
Mean (range) follow up time in months | 24.4 (2–79) | 30.2 (7–70) | 26.4 (2–84) | 31.2 (7–76) |